TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28641153
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg for 24 months
Study: 28641153
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg for 24 months
Study: 20601740
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (BC) 25 g per day for 10 weeks
Study: 16282947
Drug: palivizumab (Synagis)
Normalized name: palivizumab Injection [Synagis]
DrugBank: Palivizumab (DB00110)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: palivizumab (Synagis) 15 mg/kg, 5 monthly doses
Study: 8535541
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR monotherapy
Study: 1966794
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH), subcutaneous injection once daily
Study: 1966794
Drug: Placebo, subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneous injection once daily
Study: 22036858
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with treatment guidelines (damage control, transfusions, mechanical ventilation)
Study: 17326544
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after 18 months of therapy
Study: 16858169
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg/d orally for 7 days
Study: 16858169
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/d orally for 7 days
Study: 16858169
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg orally as a single dose
Study: 8563868
Drug: Controlled-release mesalazine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release mesalazine (1500 mg/day)
Study: 8563868
Drug: Sulfasalazine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (3000 mg/day)
Study: 2539714
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 or 40 mg once daily)
Study: 778569
Drug: Dihydergot (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydergot (1.0 mg i.m.)
Study: 31041805
Drug: Elastic band
Normalized name: elastic bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic band training programme (twice a week for 8 weeks)
Study: 26037632
Drug: 450 ml
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 ml beetroot juice (5.5 mmol nitrate)
Study: 22817699
Drug: Transdermal tulobuterol
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal tulobuterol patch (TP; 2 mg, once a day)
Study: 22817699
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 µg, twice a day)
Study: 18344636
Drug: Transdermal tulobuterol
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal tulobuterol patch (TP)
Study: 20108779
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg daily + Bicyclol 150 mg daily for 48 weeks
Study: 20108779
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg daily alone for 48 weeks
Study: 16452737
Drug: DepoDur 20
Normalized name: DepoDur 20mg/2ml Extended-Release Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoDur 20 mg
Study: 16452737
Drug: DepoDur 30
Normalized name: morphine sulfate liposomal Injection [Depodur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoDur 30 mg
Study: 16452737
Drug: Sham epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham epidural injection
Study: 15283931
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) containing 2 mg 17‐beta estradiol plus 1 mg norethisterone acetate daily for 6 months
Study: 12713610
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ornidazole vaginal ovules (VO)
Study: 12713610
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ornidazole vaginal tablets (VT)
Study: 10451129
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg x kg(‐1) promethazine i.m. prior to discharge
Study: 8841149
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray
Study: 28917229
Drug: 33 g
Normalized name: lancets 33 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 g peanut butter (PBG)
Study: 28917229
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g lard (LG)
Study: 28917229
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg [13C10] retinyl acetate capsule (reference dose) with PBG
Study: 28917229
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg [13C10] retinyl acetate capsule (reference dose) with LG
Study: 16489694
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ritodrine sustained release capsules three times a day (study group, n=62)
Study: 16489694
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n=58)
Study: 14749094
Drug: Pregnenolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (15 mg PO per day for 2 weeks followed by 30 mg PO per day for 2 weeks)
Study: 11338300
Drug: Benzocaine-gel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine-gel preparation (BGP)
Study: 8197085
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of HBO therapy administered at 4 months intervals
Study: 8197085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (8 IDDM patients, no treatment)
Study: 30093449
Drug: Alisertib tablets
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib tablets (60 mg/m2/dose × 7 days), irinotecan (50 mg/m2/dose i.v. × 5 days), and temozolomide (100 mg/m2/dose orally × 5 days)
Study: 30093449
Drug: Alisertib oral
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib oral solution (45 mg/m2)
Study: 30093449
Drug: Alisertib tablets
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib tablets (60 mg/m2/dose)
Study: 24227801
Drug: 5 mg/mL
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/mL TID pazopanib eye drops
Study: 24227801
Drug: 2 mg/mL
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/mL TID pazopanib eye drops
Study: 24227801
Drug: 5 mg/mL
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/mL QD pazopanib eye drops
Study: 20434603
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice with FES
Study: 20434603
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice without FES
Study: 12784106
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day for 30 days
Study: 8780339
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (RS2) 30 g/d
Study: 8780339
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (RS3) 30 g/d
Study: 1361083
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 mu/g) inhaled twice daily
Study: 1361083
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mu/g) inhaled 4 times daily
Study: 3969207
Drug: Bromocriptine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (20 mg maximum daily dosage)
Study: 3969207
Drug: Bromocriptine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (average dosage of 13 mg)
Study: 26953983
Drug: Watch-and-wait treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watch-and-wait treatment (nonoperative treatment)
Study: 18277740
Drug: Oral-B Triumph
Normalized name: Triumph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Triumph with FlossAction brush head
Study: 16305725
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg daily for 6 weeks
Study: 16305725
Drug: Budesonide for
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide for treatment of clinical relapse
Study: 11943525
Drug: Postoperative continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative continuous epidural droperidol infusion (2.5 mg/day)
Study: 11943525
Drug: Intraoperative single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative single IV injection of droperidol (2.5 mg)
Study: 11943525
Drug: Intraoperative IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative IV injection of droperidol (2.5 mg) and postoperative continuous epidural droperidol infusion (2.5 mg/day)
Study: 2545721
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B treatment
Study: 27966784
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual waitlist
Study: 30556414
Drug: Desoximetasone 0.25%
Normalized name: DESOXIMETASONE 0.25% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone 0.25% spray
Study: 21347823
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Treatment (MED)
Study: 25306451
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H)
Study: 336052
Drug: Levamisole 100
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole 100 mg 4 days a week for 4 months
Study: 27692144
Drug: Salbutamol (bronchodilator)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (bronchodilator)
Study: 12138347
Drug: Saquinavir soft-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir soft-gel capsules 1200 mg three times daily + zidovudine + optional lamivudine
Study: 6123070
Drug: lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam 1 mg (Noctamid)
Study: 29524192
Drug: ChronoMag® (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChronoMag® (100 mg magnesium element)
Study: 29524192
Drug: Reference tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablet (300 mg magnesium element)
Study: 26917334
Drug: Daily-wear CLs
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-wear CLs
Study: 24184132
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg, once daily), Asunaprevir (200 mg, twice daily), BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks
Study: 22971490
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 20 ml 0.5% ropivacaine
Study: 17610807
Drug: Direct individual
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct individual therapy (SLT working individually with a child)
Study: 17610807
Drug: Indirect individual
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect individual therapy (SLTA working individually with a child)
Study: 17610807
Drug: Direct group
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct group therapy (SLT working with a small group of children)
Study: 17610807
Drug: Indirect group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect group therapy (SLTA working with a small group of children)
Study: 17610807
Drug: Direct therapy
Normalized name: Aleve Direct Therapy TENS Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct therapy from an SLT
Study: 11915063
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic (1% mepivacaine, 0.2% tetracaine, epinephrine 1:200,000) plus buprenorphine, 0.3 mg
Study: 11915063
Drug: Local anesthetic-only
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic-only axillary block, and IM buprenorphine 0.3 mg
Study: 9690311
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with chemotherapy (exact regimen not specified)
Study: 9690311
Drug: Higher radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher radiation doses, conformal radiotherapy, altered fractionation schedules, and possibly adjuvant surgery
Study: 9690311
Drug: New combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: New combined modality strategies and new drugs
Study: 31100155
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment using the sutured intravitreal fluocinolone acetonide implant
Study: 31100155
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment consisting of oral steroids and conventional steroid‐sparing immunosuppression
Study: 28371205
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg once/day
Study: 19057513
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 25 mg
Study: 20535927
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) combined with chemotherapy (FOLFOX protocol)
Study: 20535927
Drug: Chemotherapy (FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (FOLFOX protocol) alone
Study: 15574127
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ramipril alone
Study: 15574127
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sildenafil alone
Study: 15574127
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and sildenafil
Study: 15539283
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil concentrate (FOC) 1 g/14 kg body weight/day for 4 weeks
Study: 10535718
Drug: celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 200 mg daily
Study: 7786833
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg daily
Study: 20938912
Drug: Narlaprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlaprevir (800 mg three times daily without ritonavir)
Study: 20938912
Drug: Narlaprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlaprevir (400 mg twice daily with 200 mg ritonavir twice daily)
Study: 20938912
Drug: Narlaprevir (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlaprevir (with or without ritonavir) in combination with PEG‐IFN‐α‐2b
Study: 20938912
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (PEG‐IFN‐α‐2b and ribavirin treatment)
Study: 18574771
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilization, PBMC collection by leukapheresis and PBMC transplant therapy
Study: 18574771
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilization for 4 days
Study: 10412920
Drug: CoQ10 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 treatment (intravenous and intracoronary)
Study: 10412920
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CoQ10 treatment)
Study: 8585104
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 25 mg sematilide HCl
Study: 8585104
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 25 mg sematilide HCl
Study: 2180144
Drug: Carbonyl iron
Normalized name: Carbonyl Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonyl iron (100 mg orally at bedtime for 56 days)
Study: 91432
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with or without cytoreductive surgery.
Study: 31530556
Drug: Zostavax (live-attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zostavax (live-attenuated herpes zoster vaccine)
Study: 29644582
Drug: Riluzole 200
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 200 mg per day for 5 weeks
Study: 22772319
Drug: Sulfasalazine (≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (≤ 3 g/day)
Study: 9492129
Drug: Lidocaine, epinephrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine, epinephrine, and tetracaine (LET) solution
Study: 9492129
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water) solution
Study: 8060627
Drug: Transarterial brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial brachial plexus block with 60 to 70 ml of local anesthetic solution
Study: 2493800
Drug: Oral doxapram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxapram (300 mg and 600 mg)
Study: 2493800
Drug: Morphine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.12 mg kg‐1 i.m.)
Study: 2493800
Drug: Doxapram alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram alone (300 mg and 600 mg)
Study: 25960104
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 40) conducted an oral hygiene regimen: brushing twice daily with sodium fluoride dentifrice, flossing twice daily, and mouth rinsing with anti‐cavity fluoride rinse once daily.
Study: 23046948
Drug: Cocoa-nut cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-nut cream (CC)
Study: 19346370
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pafuramidine eight days before challenge
Study: 19346370
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pafuramidine the day before challenge
Study: 29889239
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg over 3 days)
Study: 3128465
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (200 micrograms/min)
Study: 3128465
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vasopressin and nitroglycerin
Study: 31581929
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (200 mmHg pressure, twice daily for 10-14 days)
Study: 31581929
Drug: Guideline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based therapy (control group)
Study: 30303980
Drug: Augmented 40mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented 40mcg HBV dose schedule
Study: 26545149
Drug: Dexmedetomidine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (group D, N=25) at 0.5 µg/kg over 10 minutes, followed by an infusion at 0.5 µg/kg/h until the end of surgery
Study: 26253520
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (PRT) with 220 g of lean red meat (raw weight) divided into two 80 g servings on training days
Study: 23866774
Drug: Artesunate-amodiaquine (ASAQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC)
Study: 21924404
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy, average of 4.1 sessions
Study: 18563311
Drug: nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol (5 mg/day)
Study: 18563311
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg/day)
Study: 10211538
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 and 500 microg twice daily